Comparison: conventional treatment/placebo | Comparison: conventional treatment/placebo | Comparison: conventional treatment/placebo | Comparison: conventional treatment/placebo | Comparison: conventional treatment/placebo | Comparison: conventional treatment/placebo | Comparison: conventional treatment/placebo |
Outcomes
|
Outcomes
|
Anticipated absolute effects a (95% CI) | Anticipated absolute effects a (95% CI) |
Relative effect (95% CI)
|
NO. of participants (studies) | Quality of the evidence (GRADE) |
Risk with conventional treatment/placebo | Risk with conventional treatment/placebo | Risk with prophylactic antibiotic treatment | ||||
Mortality rate
|
153 per 1000
|
153 per 1000
|
157 per 1000 (139 to 177) | RR 1.03 (0.91, 1.16) | 4740 (12 RCTs) | ⊕⊕⊕⊕ High b, c |
Pneumonia
|
151 per 1000
|
151 per 1000
|
142 per 1000 (119 to 168) | RR 0.94 (0.79, 1.11) | 4352 (7 RCTs) | ⊕⊕⊕⊕ High b |
Incidence of infections
|
297 per 1000
|
297 per 1000
|
214 per 1000 (172 to 21264) | RR 0.72 (0.58, 0.89) | 4517 (8 RCTs) | ⊕⊕⊕ Moderate b, d |
Urinary tract infections
|
100 per 1000
|
100 per 1000
|
39 per 1000 (30 to 49) | RR 0.39 (0.3, 0.49) | 4352 (7 RCTs) | ⊕⊕⊕⊕ High b |
The proportion of patients with mRS ≤ 2
|
275 per 1000
|
275 per 1000
|
327 per 1000 (267 to 399) | RR 1.19 (0.97, 1.45) | 4385 (9 RCTs) | ⊕⊕⊕ Moderate b, e |
NIHSS score
|
The mean NIHSS was 0
|
The mean NIHSS was 0
|
MD 4.89 lower (5.84 lower to 3.94 lower)
|
-
|
160 (2 RCTs) | ⊕⊕ Low f |
Length of hospital stay
|
The mean length of hospital stay was 0
|
The mean length of hospital stay was 0
|
MD 0.23 lower (0.66 lower to 0.2 higher)
|
-
|
3839 (3 RCTs) | ⊕⊕⊕ Moderate b, g |